NO983823D0 - FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress - Google Patents

FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress

Info

Publication number
NO983823D0
NO983823D0 NO983823A NO983823A NO983823D0 NO 983823 D0 NO983823 D0 NO 983823D0 NO 983823 A NO983823 A NO 983823A NO 983823 A NO983823 A NO 983823A NO 983823 D0 NO983823 D0 NO 983823D0
Authority
NO
Norway
Prior art keywords
stress
preparation
changes due
cellular changes
irreversible cellular
Prior art date
Application number
NO983823A
Other languages
English (en)
Other versions
NO983823L (no
Inventor
Guy Miller
Lillian Lou
John Nakamura
Original Assignee
Galileo Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galileo Lab Inc filed Critical Galileo Lab Inc
Publication of NO983823D0 publication Critical patent/NO983823D0/no
Publication of NO983823L publication Critical patent/NO983823L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO983823A 1996-02-23 1998-08-20 FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress NO983823L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/607,022 US5801159A (en) 1996-02-23 1996-02-23 Method and composition for inhibiting cellular irreversible changes due to stress
PCT/US1997/002945 WO1997030713A1 (en) 1996-02-23 1997-02-20 Method and composition for inhibiting cellular irreversible changes due to stress

Publications (2)

Publication Number Publication Date
NO983823D0 true NO983823D0 (no) 1998-08-20
NO983823L NO983823L (no) 1998-10-01

Family

ID=24430472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983823A NO983823L (no) 1996-02-23 1998-08-20 FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress

Country Status (7)

Country Link
US (1) US5801159A (no)
EP (1) EP0935466A1 (no)
JP (1) JP2000506834A (no)
AU (1) AU1974997A (no)
CA (1) CA2247461A1 (no)
NO (1) NO983823L (no)
WO (1) WO1997030713A1 (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
AU744902B2 (en) * 1997-09-11 2002-03-07 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
DE69904257T2 (de) * 1999-01-20 2003-04-17 N.V. Nutricia, Zoetermeer Säuglingsnährpräparat
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US6849735B1 (en) * 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
ES2385931T3 (es) 2000-07-07 2012-08-03 Spectrum Pharmaceuticals, Inc. MÉTODOS PARA EL TRATAMIENTO DE NEUROPATíA PERIFÉRICA INDUCIDA POR UNA ENFERMEDAD Y AFECCIONES RELACIONADAS.
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6759427B2 (en) 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
WO2003006613A2 (en) * 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Methods for ex vivo propagation of somatic stem cells
US7645610B2 (en) * 2002-02-15 2010-01-12 Massachusetts Institute Of Technology Hepatocyte precursor cell lines
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
WO2003099297A1 (en) * 2002-05-21 2003-12-04 Abbott Laboratories Treatment of mucositis
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
EP1532108B1 (en) * 2002-07-29 2016-06-29 Cardax Pharma, Inc. Astaxanthin esters for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
WO2004044194A2 (en) * 2002-11-07 2004-05-27 Rensselaer Polytechnic Institute Calmodulin independent activation of nitric oxide synthase by nadph analogs
JP2006517807A (ja) * 2002-12-30 2006-08-03 パーデュー・リサーチ・ファウンデーション 中枢神経系の損傷の治療方法
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
CA2564066A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
DK1758596T3 (da) * 2004-05-26 2010-07-26 Inotek Pharmaceuticals Corp Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf
US7655465B2 (en) * 2004-06-07 2010-02-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of somatic hair follicle stem cells
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
JP4724810B2 (ja) * 2005-03-02 2011-07-13 財団法人ヒューマンサイエンス振興財団 ポリ(adp−リボース)代謝のバイオマーカーとしてのリボシルアデノシンおよびリボシルイノシン
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
DK1888059T3 (en) * 2005-06-01 2015-03-30 Edison Pharmaceuticals Inc Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
WO2007002228A1 (en) * 2005-06-23 2007-01-04 Massachusetts Institute Of Technology Methods for ex vivo propagation of adult hepatic stem cells
ITRM20050391A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
CN101453984A (zh) * 2006-03-31 2009-06-10 艾登欧比公司 使用腺苷和肌苷组合用于诊断和治疗的组合物、方法和试剂盒
EP3018122B1 (en) 2007-11-06 2018-10-10 BioElectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2974482C (en) 2008-10-28 2019-10-29 Bioelectron Technology Corporation High purity alpha tocotrienol quinone and processes for preparing same
BRPI1013376A8 (pt) 2009-04-28 2017-07-11 Edison Pharmaceuticals Inc Uso de quinonas de tocotrienol,preparação farmacêutica compreendendo as ditas quinonas e uso desta
EP2470168B1 (en) * 2009-08-26 2018-01-31 BioElectron Technology Corporation Methods for the prevention and treatment of cerebral ischemia
SG10201502588UA (en) 2010-01-11 2015-05-28 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
EP2601287B1 (en) * 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
US9162957B2 (en) 2011-07-19 2015-10-20 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
PL227045B1 (pl) * 2012-09-14 2017-10-31 Blirt Spółka Akcyjna Płyn do przechowywania narządów w czasie zabiegów chirurgicznych, zwłaszcza transplantacji.
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品
EP3233786B1 (en) 2014-12-16 2022-03-16 PTC Therapeutics, Inc. Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩
ES2968957T3 (es) 2018-10-17 2024-05-14 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciclohexa-2,5-dieno-1,4-diona para la supresión y el tratamiento de alfa-sinucleinopatías, taupatías y otros trastornos
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
US5145771A (en) * 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5320846A (en) * 1991-04-17 1994-06-14 New England Deaconess Hospital Corp. Method and composition for testing patients with metabolic depleting diseases
WO1994000008A1 (en) * 1992-06-26 1994-01-06 Torii & Co., Ltd. Organ preserving fluid
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same

Also Published As

Publication number Publication date
WO1997030713A1 (en) 1997-08-28
CA2247461A1 (en) 1997-08-28
NO983823L (no) 1998-10-01
JP2000506834A (ja) 2000-06-06
US5801159A (en) 1998-09-01
AU1974997A (en) 1997-09-10
EP0935466A1 (en) 1999-08-18

Similar Documents

Publication Publication Date Title
NO983823D0 (no) FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress
NO20012774L (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
NO973464D0 (no) Forlengingsrör - avskraperpluggapparat og fremgangsmåte
DK0850948T3 (da) Propiophenonderivater og fremgangsmåde til fremstilling deraf
DK199800913A (da) Fremgangsmåde til at påføre beskyttende og dekorativ coating på en genstand
IS2768B (is) Aðferð og búnaður til vigtunar
IS4311A (is) Setin 1H-imíðazól, aðferð til framleiðslu þeirra og notkun þeirra
NO20002421L (no) Kompositt-broplugg for lave trykk og høye temperaturer
FI981133A0 (fi) Mittausmenetelmä ja -järjestelmä
NO20003070L (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
NO20000695D0 (no) Fiberstruktur og fremgangsmÕte for fremstilling derav
NO20012289L (no) Anordning og fremgangsmåte for innretting
DK1109625T3 (da) Pulverisator og fremgangsmåde til pulverisering
NO983641D0 (no) Fremgangsmåte til behandling og farmasöytisk preparat
DK0831098T3 (da) Mellemprodukter og fremgangsmåde til fremstilling af olanzapin
EE9900141A (et) Keerdotstega suletav pakend ja meetod pakendamiseks
NO20006059L (no) Sammensatt element og fremgangsmåte for anvendelse
NO20012011D0 (no) Fremstilling og anvendelse av stivnede oljer
NO932282D0 (no) Oljeaktig preparat og fremgangsmaate for fremstilling av dette
DK0925292T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede chromanolderivater
NO990914D0 (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
IS6368A (is) Aðferð við að skera í sundur afurðir og tæki til að beita aðferðinni
NO20005763L (no) DHEA-sammensetning og fremgangsmåte
DK0940352T3 (da) Æske til produkter, der skal holdes kolde og anvendelse af en sådan æske
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application